Navigation Links
ImmusanT Relocates Offices to State-of-the-Art Innovation Facility
Date:8/16/2012

CAMBRIDGE, Mass., Aug. 16, 2012 /PRNewswire/ -- ImmusanT, Inc. announced today that it has relocated its operations to One Kendall Square, a 676,000-square-foot, mixed-use campus in the heart of Cambridge. The facility allows ImmusanT to establish a state-of-the-art lab for conducting immunologic assays to support its development efforts and clinical trials in celiac disease and other autoimmune diseases.

One Kendall Square is a nine-building campus located just minutes from Massachusetts Institute of Technology offering office, laboratory and retail space. Building 200 offers new incubator space and provides ImmusanT with its own lab facility as well as shared services that allow the company to remain capital efficient as it advances its development and discovery programs. The ImmusanT lab will specialize in a variety of high-throughput immune monitoring techniques, and the accompanying office space will accommodate the company's small executive team.

"We spent a considerable amount of time assessing options to allocate our resources toward our offices and lab. At One Kendall Square we're part of a thriving hub of innovation and it's a great environment in which to build our business," said Leslie Williams, President and CEO of ImmusanT. "Our new immune monitoring lab will allow us to sustain and better monitor critical aspects of our Nexvax2® development program and we feel it is vital in ensuring efficiency, quality and retention of expertise in-house."

ImmusanT worked directly with its broker, T3 Advisors to complete the lease agreement with The Beal Companies.

About ImmusanT, Inc.
ImmusanT is a privately-held biotechnology company focused on restoring tolerance to gluten in celiac disease by harnessing new discoveries in immunology that aim to improve diagnosis and treatment and return patients to a normal diet, good health and improved quality of life. The company is developing Nexvax2®, a therapeutic vaccine for celiac disease, and a companion diagnostic and monitoring tool to improve celiac disease management. ImmusanT's targeted immunotherapy discovery platform can be applied to a variety of epitope-specific autoimmune diseases. Founded in 2010, ImmusanT is backed by Vatera Healthcare Partners. More information can be found at www.ImmusanT.com.


'/>"/>
SOURCE ImmusanT, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Ultragenyx Relocates Company Headquarters to Support Operational Expansion
2. Forum Extended Care Services Announces Plans to Move to Larger, State-Of-the-art Facility
3. Specialty Silicone Fabricators Inaugurates New State-of-the-Art Facility in Paso Robles
4. Center for Medicare & Medicaid Innovation Awards $19 Million Grant to Develop Oncology Medical Home Model
5. Elekta to Showcase Revolutionary Agility Beam-shaping Innovation at Radiation Physics Annual Meeting
6. Young Innovations, Inc. Board of Directors Declares Quarterly Dividend
7. Sanofi US Launches Collaborate Activate Innovation Challenge
8. Joslin Diabetes Center Convenes Leaders in Diabetes Prevention, Treatment, Payment, Education and Research at Diabetes Innovation 2012
9. Siemens Unveils New Solutions and Latest Innovations at AACC 2012
10. Young Innovations, Inc. Provides 2nd Quarter Conference Call Details
11. Frost & Sullivan 2012 New Product Innovation in Bioanalytics Awarded to Protea Biosciences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... April 20, 2017  CVS Pharmacy, the retail ... a new store design to enhance the retail ... food, health-focused products and expanded beauty selections paired ... customers discover new offerings. Together with its innovative ... of the customer experience at CVS Pharmacy.  ...
(Date:4/20/2017)... , April 20, 2017 NeuroVive Pharmaceutical ... today announced positive preclinical results demonstrating anti-fibrotic ... for non-alcoholic steatohepatitis (NASH), in an additional ... NV556 has previously shown similar anti-fibrotic ... Today, NeuroVive,s scientists present novel data demonstrating ...
(Date:4/19/2017)... 19, 2017  IRIDEX Corporation (Nasdaq: IRIX ... for the first quarter 2017 after the close of ... team will host a corresponding conference call beginning at ... Investors interested in listening to the conference call may ... or (703) 326-3030 for international callers, using conference ID: ...
Breaking Medicine Technology:
(Date:4/26/2017)... ... 26, 2017 , ... Journal of Oral Implantology – Tooth loss ... overall dental health, including complications with speech, eating, and overcompensation of mouth due to ... lost teeth. As the number of tooth replacements increase, it is imperative to design ...
(Date:4/26/2017)... ... 2017 , ... The National Business Research Institute (NBRI) is ... Emergency Medical Technicians and welcomes this organization to the NBRI Circle of ... Ph.D. , CEO & Organizational Psychologist at NBRI. “This award is a result ...
(Date:4/26/2017)... ... April 26, 2017 , ... New SUPRO® XT55 Isolated ... beverages by helping beverage manufacturers more effectively manage protein costs. “Soy protein has ... as well as more stable pricing over time. Now it’s even more relevant ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... ... they have signed an agreement to be the preferred physical therapy provider for ... and returning them to Derby City CrossFit as quickly and effectively as possible, ...
(Date:4/25/2017)... ... April 25, 2017 , ... The doctors at Wall Centre Dental ... with dental fear and require sedation to receive dental care. The doctors offer three ... procedures, from hygienic cleanings to oral surgery, at their dental office in Vancouver. Wall ...
Breaking Medicine News(10 mins):